Alzheimer’s drug results leave Lilly ‘excited’ but uncertain
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
Home » Search
Search Results
4,414 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Lilly’s Alzheimer’s drug trials show mixed results
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
Web services firm plans downtown office, 300 jobs
San Francisco-based cloud-computing service provider Appirio Inc. said it will spend $2 million to open an office in downtown Indianapolis’ Pan Am building, where it will employ 300 by 2015.
Company news
North Carolina-based Quintiles, a contract researcher for drug companies, will lease 12,000 square feet in the Pan Am building for the next five years in a move to get closer to Eli Lilly and Co., one of its major clients. The office, which initially will employ 50 people, is a collaborative project of the two companies, Quintiles spokesman Phil Bridges told the Triangle Business Journal. “The goal of the collaboration has been to develop an integrated approach to optimizing how [human drug] trials are conducted, eliminate costly inefficiencies and use ‘big data’ to drive better drug development decisions,” Bridges said. The office could employ as many as 65 by the end of the year.
Here’s one way to win over skeptical locals in your hometown market: spend $1 million. Indianapolis-based hospital system Indiana University Health, which took that name last year after being called Clarian, will give $1 million to Purdue University to help build a facility that will, in part, house a satellite campus of the IU School of Medicine. IU Health was formed in 1996 by a partnership between the IU medical school and Indianapolis’ Methodist Hospital. IU Health operates one of its hospitals, IU Health Arnett, in the back yard of Purdue’s main campus in West Lafayette. When they made the name change, IU Health executives acknowledged it might present challenges in Lafayette, but they said market research showed the name still was preferred to the vanilla Clarian.
The recent sale of a California-based medical device company sent some money back to Indiana. MindFrame Inc. was acquired for $75 million by Massachusetts-based Covidien Inc. That produced an undisclosed return for Indianapolis-based CHV Capital, the venture capital arm of the Indiana University Health hospital system as well as SV Life Sciences, a Boston-based venture capital firm that has received funds from the $58 million INext Fund raised by Indianapolis-based life sciences development group BioCrossroads. MindFrame develops devices for minimally invasive removal of blood clots from stroke patients. In addition to the cash from Indiana, the company also received technical help from students at Rose-Hulman Institute of Technology in Terre Haute and some consulting advice from participants in the Indiana Clinical and Translational Sciences Institute. “Our relationship with CHV Capital and IU Health became an important element of creating value in the business and was a natural extension of our fund-of-fund relationship with BioCrossroads and INext,” said David Milne, managing director of SV Life Sciences.
ICVA eyes funds from sale by CIB of downtown’s Ober building
The Capital Improvement Board wants to plug a $2 million funding hole that will open up next year for the Indianapolis Convention & Visitors Association with the expiration of a $5.9 million grant from the owner of the JW Marriott hotel downtown.
Q&A
Alph Bingham spent more than 28 years at Eli Lilly and Co. and from there co-founded InnoCentive Inc., a Massachusetts-based organization that organizes crowdsourcing to help companies solve internal challenges. The Carmel resident spoke about the challenges now facing pharmaceutical companies, which are buckling under ever-rising costs to develop drugs with lower rates of success and worsening prospects for reimbursement. Bingham’s solution is for pharma to embrace crowdsourcing and other “open innovation” concepts in order to spread the risk of R&D among more partners.
Company news
WellPoint Inc. director Lenox Baker said there is no move on the company’s board to oust CEO Angela Braly even after an institutional investor said last week she needs to go. “Angela, I think, has done a great job,” Baker, a retired cardiac surgeon, told Bloomberg News. “Quite frankly, I think some of this stuff with the company is coming from Wall Street. I’m much more looking to the future.” WellPoint, the second-biggest U.S. health insurer, reported earnings last month that missed analyst estimates, said it would lose 900,000 members, and reduced its 2012 forecast. Those announcements prompted Leon Cooperman, whose hedge fund Omega Advisors owns 2.1 million WellPoint shares, to tell Bloomberg: “There’s a universal view that the CEO is the wrong CEO to lead the business.” Since Braly became chairwoman of WellPoint in 2010, the company’s stock price has fallen 8.5 percent. During the same time, Minnesota-based UnitedHealth Group has seen its stock rise 53 percent. The results “put an exclamation point on the differences between United and WellPoint,” Carl McDonald, a Citigroup analyst in New York, wrote in a note to clients. “Time may be running out for WellPoint’s management team.”
Eli Lilly and Co. will receive more than $1.2 billion in early payments from its former drug development partner Amylin Pharmaceuticals Inc. The payments come after Lilly competitor Bristol-Myers Squibb Co. finished its $5 billion acquisition of Amylin. Indianapolis-based Lilly partnered with California-based Amylin to launch the diabetes drugs Byetta and Bydureon. But a dispute arose between the two companies after Lilly launched another diabetes drug, Tradjenta, in partnership with Germany-based Boehringer Ingelheim GmbH. Lilly intends to use the Amylin payments to pay development costs of new drugs it hopes to bring to market.
Dr. Craig Brater will retire in June next year as dean of the Indiana University School of Medicine, he announced Wednesday, and the school has formed a committee to find his replacement. Brater, 66, has worked at the Indianapolis-based school for 26 years, including the past 12 as dean. The school is the second-largest medical school in the nation and the only one in Indiana. Brater oversees a massive operation that includes a main campus in Indianapolis and eight satellite campuses throughout the state. The medical school had a budget of nearly $426 million in the last school year, up 30 percent over the past five years. It employs 1,900 professors who oversee a total student body of 1,880 and also serves doctors at five hospitals in Indianapolis, including Wishard Memorial Hospital, the Roudebush Veterans Affairs Medical Center, and IU Health’s University Hospital and Riley Hospital for Children. Brater is a native of Oak Ridge, Tenn. He attended undergraduate and medical school at Duke University. Before IU, he was part of the faculty at the University of California at San Francisco and worked for the University of Texas Southwestern Medical Center.
Alzheimer’s quest puts Lilly to test
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
Lilly to book $790M Amylin payment in third quarter
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Brater to retire as dean of IU medical school
Dr. Craig Brater, 66, has worked at the Indianapolis-based school for 26 years, including the past 12 as dean. The school is the second largest medical school in the nation and the only one in Indiana.
Lilly stock slips after competitors halt Alzheimer’s plans
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
Despite funding dip, IU bets on brains
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
Next up for Indiana biotech: Feed the world
Even though the potential payoff for health care innovation is less certain these days, the business case for new ways to produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural innovation.
KETZENBERGER: Indianapolis needs more ‘Yeah’ attitude
How many times do you suppose Brian Payne heard, “Yeah, but” when he was selling the idea of a Cultural Trail?
SOUDER: Pence’s, Daniels’ populist subtleties
Steve Goldsmith was one of the brightest men to run for governor of Indiana but he lacked a populist touch.
Lilly studying how dogs sense diabetes in humans
The Indianapolis drugmaker said its scientists are investigating whether dogs' sharp sense of smell allow them to detect changes in human chemistry.
Lilly braces for decline in Europe
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.
Firm gives college kids the opportunity to run a painting business
Student Development Co. helps college students run Textbook Painting businesses, to learn the ins and outs of entrepreneurship. Thirty students in seven states are participating this summer, including 10 student entrepreneurs in Indiana.
Mega-warehouse technology subject of Aug. 1 expo
The Indy Warehouse Automation Expo will showcase new generation of scanners, cameras and radio frequency ID technology.